BioXcel Therapeutics to Present at ThinkEquity Conference
BioXcel Therapeutics (Nasdaq: BTAI), an AI-focused biopharmaceutical company specializing in neuroscience medicines, has announced its upcoming presentation at the ThinkEquity Conference in New York City. CEO Vimal Mehta and Executive VP Vincent O'Neill will deliver the presentation on Wednesday, October 30 at 2 p.m. ET.
The presentation will be accessible via live webcast on the company's website under the Events & Presentations page in the Investors & Media section. The webcast recording will remain available for 90 days following the event.
BioXcel Therapeutics (Nasdaq: BTAI), una società biofarmaceutica focalizzata sull'IA e specializzata in medicinali per la neuroscienza, ha annunciato la sua prossima presentazione alla ThinkEquity Conference a New York City. Il CEO Vimal Mehta e il VP esecutivo Vincent O'Neill terranno la presentazione mercoledì 30 ottobre alle 14:00 ET.
La presentazione sarà accessibile tramite webcast dal vivo sul sito dell'azienda, nella pagina Eventi e Presentazioni nella sezione Investitori e Media. La registrazione del webcast rimarrà disponibile per 90 giorni dopo l'evento.
BioXcel Therapeutics (Nasdaq: BTAI), una empresa biofarmacéutica centrada en la IA y especializada en medicamentos para la neurociencia, ha anunciado su próxima presentación en la ThinkEquity Conference en Nueva York. El CEO Vimal Mehta y el VP ejecutivo Vincent O'Neill realizarán la presentación el miércoles 30 de octubre a las 2 p.m. ET.
La presentación será accesible a través de una transmisión en vivo en el sitio web de la empresa, en la página de Eventos y Presentaciones en la sección de Inversores y Medios. La grabación de la transmisión estará disponible durante 90 días después del evento.
BioXcel Therapeutics (Nasdaq: BTAI), 인공지능에 중점을 둔 신경과학 의약품 전문 생명공학 회사가 뉴욕시에서 열리는 ThinkEquity Conference에서의 발표를 발표했습니다. CEO 비말 메타(Vimal Mehta)와 부사장 빈센트 오닐(Vincent O'Neill)이 10월 30일 수요일 오후 2시 ET에 발표를 진행할 예정입니다.
발표는 회사 웹사이트의 투자자 및 미디어 섹션의 이벤트 및 발표 페이지에서 실시간 웹캐스트를 통해 접근할 수 있습니다. 웹캐스트 녹화는 이벤트 후 90일 동안 이용 가능합니다.
BioXcel Therapeutics (Nasdaq: BTAI), une entreprise biopharmaceutique axée sur l'IA et spécialisée dans les médicaments en neurosciences, a annoncé sa prochaine présentation à la ThinkEquity Conference à New York. Le PDG Vimal Mehta et le VP exécutif Vincent O'Neill présenteront le mercredi 30 octobre à 14h ET.
La présentation sera accessible en direct via un webcast sur le site de l'entreprise, dans la page Événements et Présentations de la section Investisseurs et Médias. L'enregistrement du webcast restera disponible pendant 90 jours après l'événement.
BioXcel Therapeutics (Nasdaq: BTAI), ein auf KI fokussiertes biopharmazeutisches Unternehmen, das sich auf neurowissenschaftliche Medikamente spezialisiert hat, hat seine bevorstehende Präsentation auf der ThinkEquity Conference in New York City bekannt gegeben. CEO Vimal Mehta und Executive VP Vincent O'Neill werden die Präsentation am Mittwoch, den 30. Oktober um 14:00 Uhr ET halten.
Die Präsentation wird über einen Live-Webcast auf der Website des Unternehmens unter der Seite Veranstaltungen & Präsentationen im Bereich Investoren & Medien zugänglich sein. Die Aufzeichnung des Webcasts bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO, and Vincent J. O’Neill, M.D., Executive Vice President, Chief of Product Development and Medical Officer, will present at the ThinkEquity Conference in New York City. The presentation is set for Wednesday, October 30 at 2 p.m. ET.
To access a live webcast of the presentation, please visit the Events & Presentations page under the “News/Events” tab in the Investors & Media section of the Company’s website at bioxceltherapeutics.com. A webcast replay will be available for 90 days.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the Company’s planned participation in and content of the Company’s presentation at ThinkEquity Conference, including the date and time of such event. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI™, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; its lack of experience in marketing and selling drug products; the risk that IGALMI or the Company’s product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors section of the Company’s website at www.bioxceltherapeutics.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contact Information
Corporate/Investors
BioXcel Therapeutics
Erik Kopp
1.203.494.7062
Media
Russo Partners
David Schull
1.858.717.2310
Source: BioXcel Therapeutics, Inc.
FAQ
When is BioXcel Therapeutics (BTAI) presenting at the ThinkEquity Conference?
How can I watch BioXcel Therapeutics' (BTAI) ThinkEquity Conference presentation?
How long will the webcast replay of BTAI's ThinkEquity presentation be available?